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Self/non-self discrimination characterizes immunity and allows responses against pathogens but not
self-antigens. Understanding the principles that govern this process is essential for designing autoimmunity
treatments. p21 is thought to attenuate autoreactivity by limiting T cell expansion. Here, we provide direct
evidence for a p21 role in controlling autoimmune T cell autoreactivity without affecting normal T cell
responses. We studied C57BL/6, C57BL/6/lpr and MRL/lpr mice overexpressing p21 in T cells, and showed
reduced autoreactivity and lymphadenopathy in C57BL/6/lpr, and reduced mortality in MRL/lpr mice. p21
inhibited effector/memory CD41 CD81 and CD42CD82 lpr T cell accumulation without altering defective
lpr apoptosis. This was mediated by a previously non-described p21 function in limiting T cell
overactivation and overproduction of IFN-c, a key lupus cytokine. p21 did not affect normal T cell
responses, revealing differential p21 requirements for autoreactive and normal T cell activity regulation.
The underlying concept of these findings suggests potential treatments for lupus and autoimmune
lymphoproliferative syndrome, without compromising normal immunity.
p 21 (WAF1) is known mainly for its cell cycle inhibitor properties; it regulates early G1-S transition byinhibiting cyclin-dependent kinases in complexwith cyclins A and E orD1. It was initially assumed that p21
deletion would lead to extensive tumor development but p21-deficient mice are essentially cancer-free2,3.
Deficiency in p21 combined with mild autoreactive backgrounds such as 129/Sv 3 C57BL/64 or the Gadd45a-
deficient mice show severe lupus-like autoimmunity glomerulonephritis, which leads to death5,6. p212/2 mice on
the autoimmunity-resistant C57BL/6 (B6) background exhibited mild autoimmune manifestations7 and it was
suggested that p21 acts as a suppressor of autoimmunity. In one report, lack of p21 appeared to reduce disease in
autoimmune BXSB male background8, and it was considered that this controversy was probably due to the
atypical BXSB background7,9. The p21 autoimmunity-suppressing activity was reinforced by analysis of Egr-2
deficient autoreactivity-developing mice, which downmodulate p21 expression in T cells9.
Data from p212/2mice suggested a possible role for p21 in the expansion of activated but not of naı¨ve T cells7.
In a different system, increased p21 expression by CD41 T cells from elite (infection-free) HIV-exposed indivi-
duals, appeared critical for evasion of HIV infection10. In addition to regulating adaptive immune responses, p21
controls innate immunity, modulating macrophage activation through the NF-kB activation pathway11 and
inflammatory cytokine production11–13. p21 thus emerges as an important regulator of immunity that controls
innate and adaptive responses, and maintains autoimmunity development at bay14–16.
lpr (lymphoproliferation spontaneous mutation) mice deficient in Fas (CD95), show defective activation-
induced cell death (AICD) of in vitro restimulated T cells17. lpr mice develop lymphadenopathy due to accu-
mulation of double negative T cells (DN; TCRab1CD42CD82B2201), and lupus-like autoimmune disease,
probably due to CD41 T cell hyperactivation18. One of the unexplained symptoms caused by Fas deficiency is
massive hyperproliferation of DN T cells, CD41 effector (CD44hi/CD62Lhi), memory (CD44hi/CD62Llo), and
CD81 effector/memory T cells in lymphoid organs. Accumulation of effector/memory T cells is critical for
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development of autoimmunity, as they secrete large amounts of IFN-
c, a cytokine necessary for lupus development in lpr and other spon-
taneous or induced murine lupus models19–22. C57BL/6/lpr (B6/lpr)
mice develop anti-DNA antibodies and mild, non-lethal glomerulo-
nephritis, whereas lpr mice on the autoimmune-prone MRL back-
ground (MRL/lpr) show severe autoimmunemanifestations that lead
to kidney failure and death18. Humans with defective Fas/Fas ligand
(FasL) signaling develop autoimmune lymphoproliferative syn-
drome (ALPS)23–25, whose main characteristics are DN T cell accu-
mulation and lymphadenopathy development, propensity to lupus
autoimmunity, and increased risk for lymphoma.
To determine a possible therapeutic role for p21 in lupus auto-
immunity and to provide direct evidence for an effect of p21 on
autoreactive T cells, we analyzed the impact of T cell-directed over-
expression of p21 in B6, B6/lpr andMRL/lprmice.We found that p21
overexpression inhibited B6/lpr DN T cell lymphadenopathy and
decreased effector/memory T cell expansion and autoimmune symp-
toms. Further analysis revealed an unanticipated p21 capacity to
decrease the activation of effector/memory B6/lpr T cells and their
IFN-c production. p21 is a potent autoimmunity suppressor, since
when overexpressed inMRL/lprmice, efficiently reduced death rates.
Exogenous p21 effects were evident in lpr but not in control B6 mice,
indicating that autoimmune but not normal T cells require p21 to
control activation and IFN-c production. Therefore, therapeutic
approaches that target autoimmunity but not normal responses are
feasible.
Results
T cell-directed p21 expression inhibits effector/memory T cell
accumulation in B6/lpr but not in B6 mice. By two months of
age, B6/lpr mice show a predisposition to autoimmunity and begin
to accumulate memory and DN T cells in lymphoid organs, with
development of autoimmune characteristics and lymphadenopathy17.
As lack of p21 leads to increased expansion of repeatedly stimulated T
cells in vitro without affecting primary T cell responses7, we
hypothesized that directed transgenic p21 expression in B6/lpr
mouse T cells would reduce spontaneous accumulation of effector/
memory T cells and ameliorate lupus characteristics in these mice.
We generated B6 and B6/lpr mice that specifically express a human
p21 transgene in T cells under the proximal Lck promoter (B6-p21tg
and B6/lpr-p21tg), and studied the in vivo characteristics of peripheral
T cells. T cell development and differentiation in B6-p21tg mice is
normal26, as confirmed by similarity of thymic populations in B6
and B6-p21tg and in B6/lpr and B6/lpr-p21tg mice (Fig. S1).
Definition of effector and memory T cells is complex, and several
subgroups of these cell populations have been described27; here we
use the basic definition of effector (CD44hi/CD62Lhi) and memory
(CD44hi/CD62Llo) CD41 T cells. These two cell groups expand in
vivo and accumulate with age in B6mice, possibly due to exposure to
endogenous and environmental antigens. In B6/lpr mice, however,
effector/memory CD41 T cells accumulate to a much greater extent,
as confirmed at two and four months of age (Fig. 1A, B, left).
Enhanced p21 expression in T cells greatly reduced effector and
memory CD41 T cell accumulation in B6/lpr-p21tg mice at two
months, and more so at four months of age as compared to B6/lpr
mice (Fig. 1A). The transgene nonetheless did not affect the percent-
age of effector andmemory T cells in B6-p21tgmice (Fig. 1B). Even at
eightmonths of age, when effector andmemory T cells accumulate in
larger proportions, we found no difference between B6 and B6-p21tg
mice (Fig. 1B). CD41 T cells from two-month-old B6-p21tg and B6/
lpr-p21tg mice expressed high p21 transgene levels, while endogen-
ous p21was not detected in these or the equivalent B6 and B6/lpr cells
(Fig. 1C). The human p21 transgene appears as a higher molecular
weight band as compared to that of the endogenous p21. The
expression of the p21 transgene justified its effect in lowering effector
and memory B6/lpr-p21tg T cells. The results indicate that lpr T cells
require enhanced p21 expression to control T cell activation and
memory levels effectively, whereas exogenous p21 is not needed to
regulate B6 T cell activation.
p21 overexpression reduces B6/lpr CD41 T cell activation and
IFN-c production. Enhanced p21 expression severely reduced the
lpr effector/memory CD41 T cell population, which is large in these
mice. We tested whether p21 overexpression affects activation of
effector/memory T cells in B6/lpr-p21tg mice, and whether pro-
duction of inflammatory cytokines such as IFN-c was compromised
in this reduced cell population.
CD69 is a major T cell activation marker and is associated with
memory T cells28. Effector lpr T cells in lymph node showed greatly
increased CD69 levels (.4-fold) compared to the equivalent B6
population (Fig. 2A, left). This suggested increased cell activation
and corroborated the greatly augmented effector T cell population
in B6/lpr mice. In B6/lpr-p21tg mice, overexpressed p21 reduced
CD69 expression by ,50% in the effector T cell population
(Fig. 2A, top), whereas exogenous p21 had no effect on the high
CD69 levels by memory B6/lpr T cells (Fig. 2B, top). Enhanced
p21 expression thus efficiently reduced not only the elevated per-
centage of B6/lpr-p21tg effector CD41 T cells, but also their activa-
tion, as implied by sharply reduced CD69 expression. Overexpressed
p21 had no effect on CD69 expression by B6 lymph node effector and
memory T cells (Fig. 2A, B, bottom panels). The data show that
exogenous p21 affected mainly CD69-overexpressing effector B6/
lpr T cells, indicating that p21 targets the hyperactivated T cell
population.
To determine whether overexpressed p21 interfered with B6/lpr T
cell function, we measured inflammatory cytokine production in B6/
lpr and B6/lpr-p21tg effector and memory T cells. We analyzed
expression of IFN-c, IL-17 and IL-2, which are associated with the
lpr autoimmune phenotype29–32, and the degree of IL-4 secretion as a
control. Expression of IFN-c, which modulates anti-DNA antibody
production and disease development in several lupus models33, was
markedly increased by effector and memory CD41 T cells in B6/lpr
mice compared to B6 controls (Fig. 3A, B, left panels). Overexpressed
p21 led to a sharp decrease in the fraction of IFN-c-producing B6/
lpr-p21tg effector andmemory CD41T cells (Fig. 3A, B, top), but had
no effect on the equivalent B6-p21tg T cells (Fig. 3A, B, bottom).
Definition of memory T cells by the expression of CD44 and CD62L
might be inexact, and characterization of memory T cells is complex.
As bona fide memory T cells are defined as small CD44hi cells
(selected by forward/side scatter)34, we used this definition of mem-
ory T cells, and again found that p21 overexpression greatly reduced
the percentage of IFN-c-producing small B6/lpr-p21tg memory T
cells (Fig. 3C, left), but had no effect on the equivalent B6-p21tg T cell
population (Fig. 3C, right).
IL-17, another lupus-associated cytokine expressed by B6/lpr T
cells30,31, was produced by a small number of CD41 T cells (,3%)
and was unaffected by p21 overexpression (not shown). IL-2 levels
were substantially lower in B6/lprmemory T cells than in B6 controls
(3.3% vs. 10.4%; Fig. S2), in accordance with previous reports29; the
p21 transgene did not affect the difference in IL-2 expression (Fig.
S2). IL-4 expression was minimal (,1%) in T cells from all mice
tested (not shown).
The data indicate that the p21 transgene controls not only effector/
memory T cell accumulation in B6/lpr-p21tg mice, but also regulates
their intrinsic activation and IFN-c production potential.
The p21 transgene negatively regulates T cell hyperproliferation
in B6/lpr-p21tg mice. An unexplained characteristic of the lpr
mouse phenotype is the in vivo hyperproliferation of lymph node
CD41, CD81 andDNT cells19,20, which is not directly clarified by the
apoptosis defect observed in vitro. Here we used in vivo BrdU
incorporation to confirm these results, showing hyperproliferation
of B6/lpr CD41, CD81 and DN T cells compared to B6 controls
www.nature.com/scientificreports
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Figure 1 | p21 overexpression inhibits age-dependent accumulation of B6/lpr effector and memory T cells. (a) Flow cytometry of lymph node CD41 T
cells at 2 and 4 months of age showed reduced accumulation of B6/lpr-p21tg CD44hiCD62Lhi and CD44hiCD62Llo subsets compared to B6/lpr T cells.
Values showmean fromone representative experiment (n 5 4mice; p, 1025 for both subsets) of 3 performed. (b) Similar proportions of CD44hiCD62Lhi
and CD44hiCD62Llo CD41 T cells in B6 and B6-p21tg mouse lymph nodes at 2, 4 and 8 months of age. Values show mean from one representative
experiment (n 5 4 mice) of 3 performed. (c) Western blot showed high p21 transgene expression in sorted naı¨ve CD41 cells from B6-p21tg and B6/lpr-
p21tg mice. b-actin was used as a loading control. The samples were derived from the same experiment and the two gels were run and processed
simultaneously under the same experimental conditions.
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Figure 2 | p21 overexpression reduces activation of B6/lpr-p21tg CD41 T cells. Lymph node CD44hiCD62Lhi (effector) and CD44hiCD62Llo (memory)
CD41 T cells from 4-month-old B6/lpr, B6/lpr-p21tg, B6 and B6-p21tg mice were analyzed by flow cytometry. (a) Reduced CD69 expression in
B6/lpr-p21tg CD44hiCD62Lhi CD41 T cells compared with those fromB6/lprmice. Data are from one representative experiment (n 5 4mice; p, 1024) of
2 performed. CD69 levels were similar on B6-p21tg and B6 CD44hiCD62Lhi CD41 T cells. (b) Similar CD69 expression for B6/lpr-p21tg and
B6/lpr CD44hiCD62Llo CD41 T cells and the equivalent B6-p21tg and B6 cell populations. Data from one representative experiment of two performed
(n 5 4 mice each).
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(Fig. 4A, B, left panels). p21 overexpression greatly inhibited lymph
node CD41, CD81 and DN T cell hyperproliferation in B6/lpr-p21tg
mice (.2-fold, Fig. 4A), but had no effect on the in vivo proliferative
characteristics of B6-p21tg T cells (Fig. 4B).
Analysis of BrdU incorporation showed much greater prolifera-
tion of effector and memory B6/lpr mouse T cells compared to B6
controls (63% vs. 23%, and 43% vs. 28%, respectively; Fig. 4C, D, left).
Enhanced p21 expression had amajor anti-proliferative effect on B6/
lpr-p21tg CD41 T cells (.68%) compared to B6/lpr effectors
(Fig. 4C, top), with less extensive but significantly reduced prolifera-
tion in the equivalent memory T cell populations (28%) (Fig. 4C,
bottom). Enhanced p21 expression had no influence on effector or
memory T cell subsets in B6-p21tg mice (Fig. 4D).
Our results indicated that overexpressed p21 regulates hyperacti-
vation, IFN-c production and hyperproliferation of B6/lpr-p21tg
effector/memory T cells, with no effect on the B6-p21tg T cells.
These data suggest that p21 exerts its autoimmunity-suppressive
activity by controlling the increased activity and proliferation of
effector T cells.
Elevated p21 expression does not modify the apoptotic defect of
B6/lpr T cells. To determine whether the reduced hyperactivation
and IFN-c production as well as the expansion of B6/lpr-p21
effector/memory T cells were due to attenuation of the B6/lpr T
cell apoptosis defect by the p21 transgene, we used the classical
AICD protocol to compare B6/lpr and B6/lpr-p21 T cell death.
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Figure 3 | p21 overexpression reduces IFN-c production in B6/lpr-p21tg effector andmemory CD41T cells. Lymph node CD41 T cells from 4-month-
old B6/lpr, B6/lpr-p21tg, B6 and B6-p21tg mice were analyzed by flow cytometry. (a) Intracellular cytokine analysis showed reduced frequency of
IFN-c-producing cells in CD44hiCD62Lhi CD41 T cell populations from B6/lpr-p21tg compared with B6/lpr mice. Data are from one representative
experiment (n 5 4mice; p, 1022) of 2 performed. Percentages of IFN-c-producing cells were similar for B6-p21tg and B6 CD44hiCD62Lhi CD41 T cells.
(b) The frequency of IFN-c-producing CD44hiCD62Llo CD41 T cells was lower in B6/lpr-p21tg compared with B6/lpr mice. Data are from one
representative experiment (n 5 4 mice; p , 1022) of 2 performed. Percentages of IFN-c-producing CD44hiCD62Llo CD41 T cells were similar for
B6-p21tg and B6 mice. (c) Small CD44hi cells showed reduced frequency of IFN-c-producing cells in B6/lpr-p21tg compared with B6/lpr mice.
Percentages of IFN-c-producing small CD44hi CD41 T cells were similar for B6-p21tg and B6 mice.
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After primary TCR stimulation with concanavalin A (ConA) and IL-
2-dependent culture, B6, B6-p21tg, B6/lpr and B6/lpr-p21tg CD41 T
cells received a second stimulation, leading to activation of the Fas/
FasL system and apoptosis. AICD was similar in B6 and B6-p21tg T
cells after restimulation, as shown by a comparable apoptotic
hypodiploid peak and proportion of death in cell cycle profiles
(Fig. 5A, left). In these conditions, we found a similar defect in the
B6/lpr and B6/lpr-p21tg T cells, with absence of the apoptotic
hypodiploid peak due to the lpr AICD defect (Fig. 5A, right).
The results suggested that the p21 transgene had no effect on
normal or defective AICD. This was confirmed by the observation
that p21 transgene expressionwas high in B6-p21tg and B6/lpr-p21tg
T cells during AICD induction. In B6/lpr-p21 T cells, the p21tg was
highly expressed at the end of IL-2 treatment (Fig. 5B, 0 h). After
secondary stimulation, expression was maintained at 6, 12 and 24 h,
albeit at lower levels. Endogenous p21 expression was minimal at the
end of IL-2 culture: it increased in B6/lpr T cells after secondary
stimulation, and more moderately in B6/lpr-p21 T cells, probably
due to the p21 transgene overexpression, resulting in lower endo-
genous p21 levels in B6/lpr-p21 T cells (Fig. 5B). Expression of trans-
genic and endogenous p21 was similar in B6-p21tg and B6 T cell
cultures (Fig. S3).
We tested apoptosis induction, using annexin-V/propidium iod-
ide (PI) staining to confirm the cell cycle analysis results. In B6 and
B6-p21tg cultures, we observed similar frequencies of apoptotic
(annexin-V1/PI2; 33.1% and 32.3%, respectively) and post-apoptotic
dead T cells (annexin-V1/PI1; 45.5% and 43.4% respectively)
(Fig. 5C). These data indicated that p21 overexpression did not
influence normal Fas/FasL-dependent AICD. In similar experi-
ments, we carried out annexin-V/PI staining of B6/lpr and B6/lpr-
p21tg T cells; apoptosis was similarly defective for both cell types, as
indicated by the small percentage of apopotic T cells (,6%) in a time
course study (6 to 72 h). Percentages of necrotic cells were also low
(,10%) and were similar in B6/lpr and B6/lpr-p21tg T cell cultures
(Fig. 5D).
These results indicated that the p21 transgene is expressed at
different times during the AICD process, and exclude the possibility
that it acts as an apoptosis-promoting factor in B6 or in apoptosis-
Figure 4 | p21 overexpression reduces in vivo T cell hyperproliferation. (a) Transgenic p21 expression reduced in vivo BrdU incorporation by
B6/lprCD41, CD81, andDNT cells. Data showmean6 SD (n5 4mice; p, 1025 for the three T cell types). (b) Similar BrdU incorporation for control B6
and B6-p21tg CD41, CD81, and DN T cells. (c) p21 transgenic expression reduced in vivo BrdU incorporation by effector (CD44hiCD62Lhi) andmemory
(CD44hiCD62Llo) B6/lpr T cells. (d) B6 and B6-p21tg effector andmemory T cells showed similar in vivo BrdU incorporation. T cells were obtained from
2-month-old mice given BrdU in drinking water for 9 days. For (c) and (d) representative histograms are shown; mean 6 SD (n 5 4 mice).
www.nature.com/scientificreports
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deficient B6/lpr T cells. Our findings suggest that the p21 transgene
has an apoptosis-independent effect on B6/lpr-p21tgmouse effector/
memory T cells that reduces their excessive accumulation, activation
and IFN-c production.
p21 overexpression reduces B6/lpr T cell activation and prolife-
ration after repeated in vitro stimulation. We performed in vitro
stimulation studies to further examine the role of the p21 transgene
as an attenuator of B6/lpr-p21tg T cell activation and proliferation. In
a previous study of p212/2 mice, we showed that p21 controls T cell
expansion after secondary but not after primary stimulation7. Here
we found reduced expansion and activation of B6/lpr-p21tg T cells
after secondary stimulation, using a dual stimulation protocol with
an intermediate IL-2 expansion step as described above for AICD
induction. In these experiments, cultured B6/lpr and B6/lpr-p21tg T
cells proliferated similarly after primary ConA stimulation, as
measured by [3H]thymidine uptake (Fig. 6A). In contrast, we
detected a sharp decrease (.50%) in [3H]thymidine uptake in B6/
lpr-p21tg compared to B6/lpr T cells after secondary stimulation
(Fig. 6A). Results were similar after anti-CD3 and -CD28 TCR
stimulation of B6/lpr and B6/lpr-p21tg T cells (Fig. S4). Reduction
of cell cycle progression due to p21 overexpression was further
confirmed by .3-fold lower expression of the Ki-67 proliferation
marker35 in B6/lpr-p21tg than in B6/lpr T cells after secondary
stimulation (Fig. 6B). These findings were corroborated by a
marked reduction (.5-fold) in the absolute number of T cells that
divided in B6/lpr-p21tg vs. B6/lpr cultures at 72 h post-secondary
activation, whereas there were no notable differences after primary
stimulation (Fig. 6C). The p21 transgene did not significantly affect
B6-p21tg T cell [3H]thymidine uptake or the number of divided T
cells compared to B6 T cells after secondary or primary stimulation
(Fig. 7A, B). To avoid Fas-dependent apoptosis of restimulated B6
and B6-p21tg T cells, we used the caspase inhibitor zVAD
(benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) in restimu-
lation experiments. In B6/lpr and B6/lpr-p21tg secondary stimu-
lation cultures, zVAD was used as a control to confirm that it did
not influence the inhibitory effects of the p21 transgene.
We excluded the possibility that p21 overexpression in B6 T cells
affected in vivo CD41 T cell responses, since B6 and B6-p21tg mice
immunized with OVA in CFA, followed 3 weeks later by OVA chal-
lenge in IFA, showed no differences in overall memory T cell gen-
eration (Fig. 7E). Purified CD41 splenocytes from B6 and B6-p21tg
mice obtained 7 days after a second OVA boost, cultured with OVA
and irradiated splenocytes, showed a similar OVA response at 24 and
48 h postactivation (Fig. 7F). To further demonstrate that p21 does
not affect normal immune T cell responses, we immunized B6 and
B6-p21tg mice with vaccinia virus, an infection model that targets
CD81 T cells. We injected B6 and B6-p21tg mice with Modified
Vaccinia Ankara (MVA) virus36 at day 0 and day 8 and immune
responses were measured 10 days after the last dose. Splenocytes
were stimulated with the MHC class I restricted B8R20–27 viral pep-
tide37 and the response of CD81 spleen T cells was measured by
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Figure 5 | Apoptosis defect in B6/lpr T cells is unaffected by p21 overexpression. (a) Purified CD41 T cells from B6, B6-p21tg, B6/lpr and
B6/lpr-p21tg mouse spleens were ConA-stimulated and -restimulated after the IL-2 expansion phase. Cell cycle analysis at 24 h after restimulation
showed similar levels of cell death (presence of an apoptotic hypodiploid peak in cell cycle profiles) in B6 and B6-p21tg T cells. Lack of the apoptotic peak
was similar for B6/lpr and B6/lpr-p21tg T cells. Representative histograms are from three independent experiments. (b) Western blot analysis
showing endogenous and transgenic p21 protein levels at the end of the IL-2 expansion period (0 h) and at several points after ConA restimulation of B6/
lpr and B6/lpr-p21tg T cells. b-actin was used as a loading control. The samples were derived from the same experiment and the two gels were run
and processed simultaneously under the same experimental conditions. (c) Annexin-V/propidium iodide (PI) double staining at 24 h after
ConA restimulation showed similar levels of apoptotic (annexin-V1/PI2) and post-apoptotic (annexin-V1/PI1) B6 and B6/lpr-p21tg T cells. (d) Similar
cell death defects in B6/lpr and B6/lpr-p21tg T cells at various times after ConA restimulation, as shown by percentages of apoptotic and
post-apoptotic events. Apoptotic T cells are shown in red squares. (c, d) Data are representative of two independent experiments.
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Figure 6 | p21 overexpression decreases in vitro B6/lpr T cell hyperproliferation after secondary stimulation.CD41T cells fromB6/lpr and B6/lpr-p21tg
mouse spleens were ConA-stimulated (1st stimulation) and -restimulated (2nd stimulation) after the IL-2 expansion phase. (a) Transgenic p21
reduced T cell responses only after restimulation. Proliferation was measured by [3H]thymidine uptake 48 h after ConA stimulation or restimulation.
Values show mean 6 SD from one representative experiment (n 5 4 T cell preparations from distinct mice; p , 4 3 1026) of four performed. (b)
Flow cytometry showed reduced expression of the Ki-67 proliferation marker in B6/lpr-p21tg compared to B6/lpr T cells after restimulation. Data from
one representative experiment of three performed. (c) Absolute numbers of B6/lpr-p21tg T cells generated after restimulation were decreased
compared to B6/lpr T cells. Live cells were determined by trypan blue exclusion. Values show mean 6 SD from one representative experiment of three
performed (n 5 4 T cell preparations from distinct mice; p , 1027). (d) CDK2 activity after ConA restimulation. Assay products were resolved in
SDS-PAGE and phosphorylated histone (H1) was detected by autoradiography. Extracts were analyzed by Western blot for CDK2 levels as loading
control. (e) Similar percentages of B6/lpr and B6/lpr-p21tg CD44highCD62Lhigh CD41 T cells at the end of the IL-2 expansion (top). At 24 h after
restimulation, the percentage of B6/lpr-p21tg CD44highCD62Lhigh cells was decreased compared to B6/lpr (bottom). (f) Flow cytometry of CD41 T cells
for intracellular cytokines. IFN-c-producing B6/lpr-p21tg CD41 T cells were reduced compared to B6/lpr 24 h after restimulation. Values show
mean 6 SD (n 5 4 mice each; p, 1022). Differences in IL-2 were not significant (top). After restimulation with IL-2, IL-12 and IL-18, IFN-c-producing
B6/lpr-p21tg were lower compared to B6/lpr T cells. Values show mean 6 SD (n 5 3 mice, p 5 0.0013) (bottom). (g) Western blot showing ERK
phosphorylation and transgenic p21 protein levels in B6/lpr and B6/lpr-p21tg T cells after restimulation. b-actin was used as a loading control. The
samples were derived from the same experiment and the two gels were run and processed simultaneously under the same experimental conditions.
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Figure 7 | p21 overexpression does not affect B6 T cell proliferation or activation. CD41 T cells from B6 and B6-p21tg mouse spleens were ConA-
stimulated or -restimulated (in the presence of zVAD) after an IL-2 expansion phase. (a) Proliferation was measured by [3H]thymidine uptake at 48 h
after first or second ConA challenge. Values showmean 6 SD (n 5 4 T cell preparations from distinct mice). (b) Generation of newly divided B6 and B6-
p21tg T cells was similar after primary and secondary stimulation, as determined by trypan blue exclusion. Values show mean 6 SD (n 5 3 T cell
preparations from distinct mice). (c) CDK2 activity after ConA restimulation. Assay products were resolved in SDS-PAGE, and phosphorylated histone
(H1)was detected by autoradiography. Extracts were analyzed byWestern blot for CDK2 as loading control. Dotted line represents cropping of single gels.
Full-length gels are presented in Supplementary Figure 6. (d) ERKphosphorylation and transgenic p21 protein levels in B6 and B6-p21tg T cells at various
times post-restimulation. b-actin was used as a loading control. (e) Lymph nodes from OVA-immunized and –boosted B6 and B6-p21tg mice were
analyzed to quantifymemory CD41 T cells. (f) Purified CD41 splenocytes were fromOVA-immunized and -boosted B6 and B6-p21tgmice were cultured
with OVA and irradiated splenocytes, and showed similar [3H]thymidine uptake at 24 and 48 h postactivation. Data are representative from two
experiments (n 5 4 mice each). (g) Splenocytes from vaccinia-injected B6 and B6-p21tg mice were cultured with vaccinia peptide after double in vivo
immunization, and showed similar specific CD8 T-cell immune responses, as detected by the proportions of IFN-c- and TNF-a-producing cells. The
non-specific responses obtained in the absence of vaccinia peptide were substracted. Data show mean 6 SD (n 5 5 mice).
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determining the proportion of IFN-c- and TNF-a-expressing CD81
T cells. We found similar responses for B6 and B6-p21tg CD81 T
cells after immunization and restimulation (Fig. 7G).
Our data show that, as in the in vivo studies, p21 limits expansion
of B6/lpr-p21tg but not of B6-p21tg T cells in in vitro restimulation
conditions. As p21 inhibits CDK2 and regulates proliferation, we
examined CDK2 activity in B6/lpr-p21tg T cells after secondary
stimulation; at 24 h post-stimulation, we found reduced CDK2 activ-
ity in B6/lpr-p21tg T cells (Fig. 6D), which could account for their
decreased expansion. Nonetheless, CDK2 activity was reduced in B6-
p21tg T cells compared to B6 counterparts (Fig. 7C), which showed
similar proliferation capacity after restimulation (Fig. 7A, B). These
results raise the possibility that reduction of CDK2 activity by p21
alone is insufficient to limit the increased responses of B6/lpr T cells.
In addition to its effect on in vivo hyperproliferation, the p21
transgene lowered T cell activation and IFN-c production by B6/
lpr-p21tg CD41 T cells. In the dual stimulation protocol, IL-2-
expanded B6/lpr and B6/lpr-p21tg CD41 T cell populations had sim-
ilar percentages (,10%) of effector cells with a CD44hiCD62Lhi
phenotype, suggesting that the p21 transgene had no effect on the
initial stimulation process (Fig. 6E, top). The remaining cells had a
CD44hiCD62Llo memory cell phenotype. After secondary stimulation
of B6/lpr T cells (24 h), the proportion of effectors increased from
9.6% to 35%, suggesting that a fraction of cells reverted frommemory
to effector phenotype as a result of activation (Fig. 6E, left). In B6/lpr-
p21tg cultures, conversion to effector T cells was clearly lower after
restimulation (22%; Fig. 6E, right), reflecting a lower activation level.
These data suggested that the p21 transgene negatively regulated B6/
lpr T cell activation after secondary stimulation. In accordance with
these results, a significantly smaller fraction of restimulated B6/lpr-
p21tg T cells produced IFN-c compared to B6/lpr T cells (Fig. 6F,
top). The results coincided with our in vivo data showing a limited
percentage of IFN-c-producing T cells in B6/lpr-p21tg mice. We
detected no significant differences for IL-2 production in equivalent
in vitro experiments (Fig. 6F, top). In order to provide additional
evidence for a role of p21 in reducing IFN-c production, we
employed a model were IFN-c is directly induced. IL-12 directly
drives IFN-c production, which is enhanced by IL-18 in T cells dur-
ing TCR activation38,39. In our case, T cells were initially stimulated
with ConA, subsequently exposed to IL-2 and then triggered by IL-
12, IL-18 and IL-2. Under these conditions, B6/lpr T cells showed a
high proportion of IFN-c positive cells (more than 36%), while p21
transgenic expression in B6/lpr-p21tg T cells strongly inhibited IFN-c
production (Fig. 6F, bottom). These data showed that enhanced p21
expression suppresses IL-12- and IL-18-dependent IFN-c induction.
Activation anomalies corresponding to the amount of phosphory-
lated ERK (p-ERK) are thought to enhance autoreactivity and IFN-c
production40,41; we therefore examined the regulatory effect of the
p21 transgene on ERK phosphorylation of B6/lpr and B6/lpr-p21tg T
cells.Western blot analysis showed p-ERK variations in B6/lpr-p21tg
compared to B6/lpr T cells, in a period up to 6 h after secondary
stimulation. ERK phosphorylation was lower at 0.5 and 1 h post-
stimulation, with higher p-ERK levels at 2 h post-activation in B6/
lpr-p21tg cultures (Fig. 6G). An initial delay in ERK phosporylation
thus led to larger amounts of p-ERK, a response pattern that might
cause reduced IFN-c production by B6/lpr-p21tg T cells. p21tg
expression was also confirmed after secondary activation (0–6 h;
Fig. 6G). We found no p-ERK expression differences in B6 and B6/
lpr-p21tg T cell cultures (Fig. 7D), reinforcing our view that p21
overexpression affects lpr but not normal T cells.
The results indicate that, as for B6/lpr-p21tg T cells in vivo, p21
transgene expression regulates overexpansion, overactivation and
increased IFN-c production by B6/lpr T cells in vitro.
Reduction of hyperproliferating effector/memory T cells ameli-
orates autoimmune disease manifestations in B6/lpr mice. B6/lpr
mice show mild autoimmunity compared to the lethal lupus-like
autoimmune glomerulonephritis in MRL/lpr mice; B6/lpr mice
nevertheless develop a large effector/memory T cell population as
well as anti-DNA autoantibodies and slight lymphadenopathy18. T
cell-directed p21 overexpression in B6/lprmice reduced not only the
effector/memory T cell compartment, but also activation of IFN-c
production by these cells. As IFN-c is indispensable for anti-DNA
autoantibody production19, we predicted a decrease in these
autoantibodies in B6/lpr-p21tg mice; indeed, we observed a sharp
drop in anti-DNA antibodies in B6/lpr-p21tg mouse serum
compared to B6/lpr controls (Fig. 8A). Although the effect of the
p21 transgene leads to reduced T cell activation and associated
disease manifestations, alternatively, increased p21 expression may
affect disease development in a paracrine manner. As macrophage
activation is critical for lpr disease development42, we examined
whether these cells could be affected by the p21 transgene in such
manner. Peritoneal B6/lpr macrophages were exposed to culture
supernatants from repeatedly stimulated B6/lpr or B6/lpr-p21tg T
cells. The concentration of IFN-c in T cell culture supernatants was
strongly reduced in the presence of the p21 transgene (Fig. S7).While
the supernatants from B6/lpr T cells highly activated macrophages,
as seen by high STAT1 phosphorylation and iNOS induction,
equivalent supernatants from B6/lpr-p21tg showed lower STAT1
phosphorylation and abolished iNOS induction (Fig. S7). These
data also suggest that iNOS is induced only by high IFN-c levels, a
result that was supported by exposing macrophages to different IFN-
c concentrations. Overall the results highlight the potential of p21
overexpression to control essential disease components in a
paracrine fashion.
B6/lprmice develop lymphadenopathy and splenomegaly, caused
mainly by DN T cell accumulation. Expansion of this cell subset is
evident at two months of age and increases with time. p21 over-
expression led to a clear reduction in the DN T cell population in
B6/lpr-p21tg mice (Fig. 8B). Consistent with this decrease, lympha-
denopathy was notably reduced in these mice compared to B6/lpr
controls, with greatly diminished lymph node size and weight
(Fig. 8C). We detected no endogenous p21 expression in DN T cells
(Fig. 8D). This lack of p21 probably explains the hyperproliferation
of these cells, whereas transgenic p21 expression (Fig. 8D) reduced
their hyperproliferation and hyperactivation. In agreement with the
inhibition of DN cell hyperactivation, we found a profound reduc-
tion in IFN-c- and IL-17-producing DN T cells in B6/lpr-p21tg mice
(Fig. 8E).
As DN T cells arise from CD81 T cells43 we examined the in vitro
characteristics of B6/lpr-p21tg and B6/lprCD81 T cells purified from
the spleens of 2-months-old mice. The data showed that after sec-
ondary stimulation B6/lpr-p21tg CD81 T cells proliferate at much
lower levels compared to B6/lpr CD81 T cells, as tested by cell cycle
and BrdU analyses (Fig. S8). In contrast to DN T cells which hyper-
proliferated in vivo, the DN cells, which were generated by CD81 T
cells in in vitro cultures44, accumulated as non-proliferating cells, as
shown by cell cycle and BrdU analyses. The percentage of accumu-
lated DN T cells after secondary stimulation was similar for both B6/
lpr and B6/lpr-p21tg CD81 T cell cultures (approximately 10%) (Fig.
S8), indicating that p21 affects DN T cell expansion only in vivo.
These data show that T cell-directed expression of the p21 trans-
gene had a dual effect in B6/lpr mice; first, it lessened autoimmune
manifestations, due to the transgene effect on IFN-c production, and
second, it limited DN T cell-induced lymphadenopathy by reducing
DN T cell hyperactivation and hyperproliferation.
p21 overexpression reduces lupus-like autoimmunity and incre-
ases MRL/lpr mouse survival. As p21 overexpression in B6/lpr-
p21tg T cells limited autoimmune symptoms and lympha-
denopathy in B6/lpr mice, we tested its potential to inhibit the
severe, death-inducing autoimmunity in MRL/lpr mice. T cell-
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directed p21 overexpression reduced the percentage of lymph node
DN T cells as well as lymphadenopathy development (Fig. S5) in
MRL/lpr-p21tg compared to MRL/lpr mice.
MRL/lpr-p21tg mice showed sharply reduced (.4-fold) anti-
DNA antibody levels that decreased nearly to values for MRL-Mp
controls, which develop mild autoimmunity later in life (Fig. 9A). As
MRL/lprmice have much higher anti-DNA antibody levels than B6/
lpr mice, p21 overexpression appeared to control the predisposition
to severe autoimmunity. Compared to MRL/lpr mice, MRL/lpr-
p21tg mice showed clear improvement in critical aspects of lupus-
like kidney disease such as lower immune complex deposition,
decreased inflammatory infiltration of CD41 T cells and F4/801
macrophages (Fig. 9B), and reduced glomerulonephritis (Fig. 9C).
These data were corroborated by proteinuria analysis showing sig-
nificantly reduced proteinuria for MRL/lpr-p21tg compared to
MRL/lpr mice (1.51 vs 4.01, n 5 10 mice per group; p , 1023).
This p21 transgene effect onMRL/lpr diseasemanifestations resulted
in extended survival of MRL/lpr-p21tg mice (Fig. 9D).
These findings indicate that p21 is a potent suppressor of auto-
immunity, as it can restrain autoimmune symptoms and death assoc-
iated with severe lupus-like disease in the MRL/lpr mouse model.
Discussion
Deficiency in p21 when combined with autoimmunity-prone back-
grounds leads to severe lupus-like disease and death, suggesting that
p21moderates autoimmunity progression5,6. On the other hand, lack
of p21 in normal background mice results only in mild autoreactiv-
ity7, questioning a possible effect of p21 in autoimmunity treatment.
The aim of the present study was to explore a p21 therapeutic effect
by increasing its expression levels in T cells of B6/lpr and MRL/lpr
mice.We showed that enhanced p21 levels suppressed autoreactivity
andDNT cell lymphadenopathy in B6/lpr-p21tgmice and effectively
targeted severe autoimmune disease and death in MRL/lpr-p21tg
mice and led to three principal conclusions. First, we provided direct
evidence for a role of p21 in regulating autoimmunity through a p21
function on effector/memory lpr T cells that limits their accumula-
tion, activity and IFN-c production. Second, we established that
preactivated but not naı¨ve lpr T cells require elevated p21 expression
to control activation. Finally, since normal background B6-p21tg T
cells remained unaffected by increased p21, our work imparts an
experimental model that specifically targets autoimmune, but not
normal immune responses.
In B6/lpr mice, activated T cells increase with age as effector/
memory or DN T cells. Fas deficiency leads to defective AICD in
in vitro conditions but deficient T cell apoptosis has not yet been
shown in vivo in the absence of Fas18. Instead, all lpr T cell subsets
exhibit a hyperactivation state and hyperproliferate45–47, suggesting
that alternative Fas functions may control lpr T cell proliferation24. T
cell-specific p21 overexpression severely reduces effector/memory
and lpr DN T cell expansion. We did not detect a role for overex-
pressed p21 in AICD induction, as B6/lpr and B6/lpr-p21tg T cells
showed similarly defective apoptosis after secondary stimulation,
and AICD was similar for B6 and B6-p21tg T cells. Therefore we
Figure 8 | p21 overexpresson reduces autoimmune disease manifestations in B6/lpr mice. (a) Anti-DNA IgG levels detected by ELISA in mouse
serum at 4 months of age. Anti-DNA IgG production was reduced in B6/lpr-p21tg compared to B6/lprmice. Values show mean 6 SD (n 5 9 mice; p,
1024). (b) Reduced proportions of DN T cells in B6/lpr-p21tg lymph nodes compared to B6/lpr at 5 months of age (n 5 4 mice). (c) Reduced
cervical lymph node size and weight in B6/lpr-p21tg females compared to B6/lpr at 8 months of age. Values showmean 6 SD (n 5 10mice). (d)Western
blot showed high transgenic p21 protein levels in DN T cells from 2-month-old B6/lpr-p21tg mice. Endogenous p21 is not expressed in B6/lpr or
B6/lpr-p21tg DN T cells. b-actin was used as a loading control. (e) Intracellular staining showed reduced production of IFN-c (left) and IL-17 (right) in
B6/lpr-p21tg DN T cells. Values show mean 6 SD (n 5 4 mice; p , 1022 for both cytokines).
www.nature.com/scientificreports
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ruled out the possibility that transgenic p21 reduced lpr DN and
effector/memory T cells by promoting their apoptosis. Together with
data from a previous study that showed similar apoptosis for resti-
mulated B6 andB6 p212/2T cells7, these results demonstrate that p21
is not involved in typical Fas/FasL-dependent AICD events.
Furthermore, our data suggest that the in vivo expansion of DN cells
is driven by an uncontrolled cell cycle progression, which is disso-
ciated from the absence of apoptosis.
The control of the effector/memory T cell population in B6/lpr-
p21tg mice was the result of a reduced T cell activation accompanied
by a sharp limitation of the proportion of T cells that secrete IFN-c.
These data suggest that overexpressed p21 does not act as a mere cell
cycle inhibitor and may possess other properties in controlling T cell
responses. Other studies have shown that p21 interferes with the NF-
kB activation pathway in macrophages11 or controls the anergic state
of chemically-induced T cell anergy48, independently of its cell cycle
inhibitor function. Exogenous p21 did not affect the effector/mem-
ory T cell population of normal background B6-p21tg mice and did
not influence their activation and IFN-c production. These data
indicate that endogenous p21 is sufficient to control normal T cells
and that increased p21 levels do not influence the responses of B6-
p21tg T cells. In agreement with this view, classical immunization
with OVA or with vaccinia virus showed similar responses of B6 and
B6-p21tg T cells. It is, therefore, here established that autoimmune
lpr T cells require higher p21 levels in order to control their activa-
tion, as compared to normal T cells that remain unaffected by exo-
genous p21.
In vitro studies validated the above results, showing that after
secondary stimulation B6/lpr-p21tg T cells acquired a less activated
phenotype and produced less IFN-c than those from B6/lpr mice.
Importantly, direct induction of IFN-c by IL-12 and IL-18, following
primary stimulation and IL-2 treatment, was significantly inhibited
by the p21 transgene. These findings indicate that overexpressed p21
may interfere with the IFN-c induction pathway. The decreased
proliferation of B6/lpr-p21tg T cells was accompanied by a reduction
of CDK2 activation, suggesting that exogenous p21 may target pro-
liferation through its effect on CDK2. However, B6-p21tg T cells also
showed diminished CDK2 activity but proliferated similarly to B6 T
cells. Theses results support the view that differences in CDK2 activa-
tion do not always translate into proliferation differences, as CDK2 is
a dispensable target for cell cycle inhibition49,50. Therefore, in addi-
tion to CDK2 inhibition overexpressed p21 may also modulate the
expansion of lpr T cells by altering their degree of activation.
Accordingly, p21 affected ERK phosphorylation in B6/lpr-p21tg
but not in B6-p21tg T cells. Other studies show association between
p-ERK levels and IFN-c production showing that ERK reduction
leads to decreased or increased IFN-c production by T cells40,41.
We suggest that p21-dependent alteration of ERK phosphorylation
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Figure 9 | p21 overexpression reduces autoimmune disease symptoms and mortality in MRL/lpr mice. (a) Relative anti-DNA IgG levels detected by
ELISA in serum at 4 months of age. Anti-DNA IgG production was decreased inMRL/lpr-p21tg compared toMRL/lprmice. Values showmean 6 SD (n
5 9mice; p, 2 3 1024). (b) Immunostaining of kidney cryosections, showing reduced immune complex deposition (anti-IgG), CD41 T cell (anti-CD4)
and macrophage (anti-F4/80) infiltration in MRL/lpr-p21tg mice at 6 months of age. (c) Evaluation of glomerulonephritis grade (Berdem scale) in
representative kidney sections from MRL-Mp, MRL/lpr and MRL/lpr-p21tg mice at 6 months of age showed reduced glomerulonephritis in MRL/lpr-
p21tg than in MRL/lpr mice. (d) Kaplan-Meier survival curves indicate the effect of the p21 transgene on MRL/lpr-p21tg mouse lifespan.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 7691 | DOI: 10.1038/srep07691 11
may reduce IFN-c production in restimulated B6/lpr-p21tg T cells, a
point that will be addressed in depth in a later study.
Exogenous p21 had no effect on activation and IFN-c production
capacity of restimulated B6-p21tg T cells, corroborating the in vivo
results. These data reaffirm the differential requirements of auto-
immune and normal T cells in controlling their activation state, as
p21 was similarly expressed in both cell types. Primary B6-p21tg and
B6/lpr-p21tg T cell responses were not affected, showing that p21
overexpression is specifically targeting repeatedly stimulated lpr T
cells. Thus, p21 overexpression does not inhibit autoimmunity
through a general suppression of T cell responses, a result that is
further supported by data showing that exogenous p21 does not
affect T cell development in the thymus.
p21 overexpression markedly inhibited lymphadenopathy
development in both B6/lpr-p21tg and MRL/lpr-p21tg mice. As
DN T cell hyperactivation is directly linked to their hyperprolifera-
tion and accumulation45, p21 could regulate their expansion. Indeed,
exogenous p21 greatly reduced IFN-c and IL-17 overexpression by
these cells, which is linked to hyperresponsiveness51, suggesting that
p21 regulation of T cell activity could be used in therapeutic design
for ALPS patients.
Overexpressed p21 compromised the capacity of effector/memory
B6/lpr-p21tg T cells to produce IFN-c, which is necessary for anti-
DNA autoantibody and lupus-like autoimmunity development19,42.
These results suggest that overexpressed p21 reduces T cell activation
and IFN-c secretion, which lead to downmodulation of anti-DNA
antibody production. In addition, in vitro data suggest a possible
paracrine effect of p21 transgene in disease development, since the
differential IFN-c secretion by B6/lpr and B6/lpr-p21tg T cells greatly
affected macrophage activation and inflammatory potential. MRL/
lpr mice develop severe autoimmune disease and suffer early mor-
tality due to the concurrence of the lpr mutation and the MRL
autoimmunity-promoting background. T cell-directed p21 overex-
pression strongly limited MRL/lpr-p21tg mice mortality by greatly
reducing anti-DNA autoantibody production and kidney inflam-
matory infiltrates. Furthermore, it diminished the DN T cell num-
bers, as well as their potential to produce inflammatory cytokines,
which is related to pathogenicity51. These data support a strong
therapeutic role for p21 in increased autoreactive T cell responsive-
ness and in maintaining autoimmunity at bay.
Elevated IFN-c levels are associatedwith SLE52,53, and clinical trials
are currently testing the humanized anti-IFN-c monoclonal anti-
body AMG 811 for lupus treatment (Amgen). In this context, our
results suggesting that p21 inhibits autoimmunity by modulating
IFN-c could have therapeutic interest. General alterations in the
activation machinery and reduced p21 levels in lupus patient T
cells54,55 corroborate the therapeutic potential of our findings. The
data also suggest that autoimmune memory T cell hyperresponsive-
ness can be reduced without affecting normal T cell responses, which
would evidently constitute an ideal treatment for lupus and other
autoimmune diseases. While therapeutic use of p21 overexpression
might not appear to be an immediate option in humans, analysis of
the mechanism by which high p21 levels reduce memory T cell
expansion could provide a discovery platform for p21-associated
factors suitable for clinical intervention. Finally, the selective effect
of p21 on autoimmune but not normal T cells supports the idea of
developing therapeutic approaches that do not affect normal
immunity but robustly target autoimmune pathology.
Methods
Mice. Control C57BL/6 mice were obtained from Harlan Interfauna Ibe´rica; C57BL/
6-lpr (B6.MRL-Tnfrsf6lpr) were from Jackson Laboratories. In C57BL/6-lpr-p21tg
mice, generated from C57BL/6-lpr and C57BL/6-p21tg mice, transgene expression
was restricted to T cells by the proximal Lck promoter26. Mice were kept in SPF
conditions. All mouse experiments were performed in accordance with European
Union and national regulations, and were approved by the CNB Bioethics
Committee.
Flow cytometry. Stained cells were analyzed on an LSR cytometer (Becton
Dickinson). To determine memory phenotype, CD41 T cells were stained with anti-
CD8-PEcy7 (Biolegend), -CD4-PE, -CD44-FITC and -CD62L-APC (Beckman
Coulter) antibodies. For double negative population analysis, cells were stained with
anti-CD4-FITC (PharMingen), -CD8-PEcy7, -B220-APC (Beckman Coulter) and
-TCR-PE (PharMingen) antibodies.
BrdU was detected with an anti-BrdU-FITC antibody (Becton Dickinson) com-
bined with -CD4-Pecy7 (eBioscience), -CD8-SPRD (Beckman Coulter), -CD44-biot
(PharMingen), Av-SPRD (Beckman Coulter), -CD62L-PE (Southern) and -TCR-PE
(PharMingen) antibodies. To distinguish live from dead cells, we preincubated cells
with the LIVE/DEAD stain kit (Invitrogen) according tomanufacturer’s instructions.
Only live cells were considered for analyses.
Cell culture. Mouse CD41 spleen T cells were purified by Negative Isolation Kit
(Dynal Biotech);.85% pure CD41 T cells were obtained. In some experiments, naı¨ve
CD41/CD44low/CD62Lhi cells were obtained by a combination of negative isolation
and sorting on an Epics Altra sorter (Beckman Coulter) after staining with anti-CD44
and -CD62L antibodies. Purified naı¨ve T cells (106/ml) were stimulated in vitro with
concanavalin A (ConA; 3 mg/ml, Sigma) in medium containing 20 ng/ml human
recombinant interleukin-2 (rIL-2, PeproTech) or in medium conditioned with anti-
CD28 (PharMingen; 1 mg/ml) in wells coated with anti-CD3 antibody (PharMingen;
1 mg/ml in 100 ml/well PBS). After 3 days, cells were washed and cultured in medium
with 20 ng/ml IL-2 (24 h), followed by restimulation with IL-2 in combination with
either ConA or anti-CD3/CD28 or IL-12 (10 ng/ml) plus IL-18 (10 ng/ml). In some
cultures, the caspase (zVAD; 50 mM/ml, Bachem) was added.
Mouse CD81 T cells were isolated from spleen by a negative isolation kit
(Dynabeads Untouched Mouse CD8 cells, Invitrogen) and stimulated in vitro with
ConA (3 mg/ml, Sigma) in complete RPMI, containing 20 ng/ml human recombin-
ant interleukin-2 (rIL-2, PeproTech). After 3 days, cells were washed and cultured in
medium with 20 ng/ml rIL-2 (24 h), followed by ConA restimulation for 24 h.
During the last 3 hours, BrdUwas added at a final concentration of 6.5 mg/ml and the
cells were processed for flow cytometry and stained with the combination of anti-
TCRb, anti-CD8, anti-CD4 and anti–BrdU antibodies. Alternatively, cells were
stained with anti-CD8-PE and 2 mg/ml 49,6-diamidino-2-phenylindole (DAPI) for
cell cycle analysis.
Formacrophage cultures, peritonal exudate cells (PEC) were harvested fromB6/lpr
mice that were injected i.p. with 1 ml of 3% thioglycollate medium (Difco) 4 days
before isolation. PEC were cultured for 2 h in RPMI 1640 without FBS and non-
adherent cells were removed by washing with PBS and adherent macrophages were
cultured overnight in complete RPMI 1640 with 10% FBS. Cells were incubated for
20 h in the presence of 152 diluted cell-free culture supernatants from B6/lpr or B6/
lpr-p21tg T cells (collected 24 h after second ConA stimulation). Control cells were
cultured inmedium alone or stimulated for 20 hwith IFN-c (100 or 50 U/ml, Sigma).
OVA immunization and in vitro stimulation. B6 and B6-p21tg mice were
immunized with 100 mg OVA (Sigma-Aldrich) and CFA as previously described7.
After 3 weeks, mice received a second OVA boost in IFA; mice were sacrificed one
week later and lymph node cells were stained to quantify memory CD41 T cells. In
addition, CD41 cells were purified from spleens of B6 and B6-p21tg mice one week
after the secondOVAboost usingDynabeads as above. Cells were OVA-stimulated in
vitro (100 mg/ml; 105 cells/ml; 24 h) in RPMI 1640 containing 10% FCS with
irradiated splenocytes (0.5 3 106/ml). Proliferation was measured using
[3H]thymidine as above.
Vaccinia virus infection and in vitro stimulation. B6 and B6-p21tg mice were
immunized by i.p. injections at Day 0 and Day 8 with 1 3 107 PFU of Modified
Vaccinia Ankara (MVA) virus36. At Day 18, mice were sacrificed and erythrocyte-
depleted spleen cells were resuspended in RPMI 1640 with 10% FCS and 1 mg/ml
GolgiPlug (BD) and stimulated (6 h, 37uC, 5%CO2)with B8R20–27 peptide of vaccinia
virus (sequence: TSYKFESV, CNB, Proteomics Facility) at a final concentration of
10 mg/ml.
Intracellular cytokine staining. For intracellular cytokine staining, lymph node T
cells or cells after primary ConA activation and IL-2 expansion were stimulated (1 h,
37uC) in medium with phorbol 12-myristate 13-acetate (PMA; 50 ng/ml) and
ionomycin (2 mg/ml). Brefeldin A (GolgiPlug, 20 ml/ml; BD PharMingen) was added
and cells incubated (3 h, 37uC). After surface marker staining with appropriate
combinations of labeled anti-CD4, -CD8, -Thy1, -CD44, and -CD62L, cells were
washed with PBS, fixed and permeabilized with Cytofix/Cytoperm (100 ml, 20 min,
4uC), washed once with Perm/Wash buffer and blocked with 150 ml Perm/Wash
buffer 1 1% BSA (30 min, room temperature (RT)). Anti-IL-17-PE, -IL-2-PE and
-IFNc-PE antibodies were added (all 1/100, PharMingen); permeabilized cells were
incubated (20 min, 4uC) and washed twice in Perm/Wash before FACS analysis.
For the vaccinia infection experiment, splenocytes were stained for surfacemarkers
with anti-CD3-PE-CF594, -CD4-APC-Cy7, -CD8-V500 (all from BD), fixed, per-
meabilized (Cytofix/Cytoperm kit; BD), and stained intracellularly with anti-IFNc-
PE, and -TNFa-PE-Cy7 (from BD). Dead cells were excluded using the violet LIVE/
DEAD stain kit (Invitrogen).
In vivo BrdU administration.Mice were given BrdU (0.8 mg/ml; Sigma-Aldrich) in
drinking water, which was prepared fresh every 2 days for a 9-day period, and BrdU
incorporation was determined in lymph node T cells. Cells were stained with
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appropriate combinations of labeled anti-CD4, -CD8 and -CD44, -CD62L and -TCR
and anti-BrdU antibody.
DN T cell sorting.Mouse CD41 T cells were isolated from spleen using the Negative
Isolation Kit, and stained with anti-TCR-FITC (Pharmingen), -CD4-PE (Beckman
Coulter) and -CD8-SPRD.DNT cells were separated from freshly isolated total CD41
T cells on an Epics Altra sorter (Beckman Coulter).
Proliferation assays. Proliferation was quantified by [3H]thymidine uptake (1 mCi/
150 ml; Amersham Bioscience) in the last 16 h of culture. After cell transfer to fiber
filters (Wallac) with a semi-automatic cell harvester, incorporated radioactivity was
measured in a beta-plate counter (b1205 Wallac, Perkin Elmer).
To measure expression of the Ki-67 proliferation marker, cells were washed with
PBS, fixed and permeabilized with Cytofix/Cytoperm (100 ml; 20 min, 4uC), washed
once with Perm/Wash buffer and blocked with 150 ml Perm/Wash buffer 1 1% BSA
(30 min, RT). Anti-Ki-67 antibody (1/100, Abcam) was added; permeabilized cells
were incubated (1 h, 4uC) and washed twice in Perm/Wash before flow cytometry
analysis.
Apoptosis assays. For cell cycle analysis, at the indicated times permeabilized cells
were resuspended in 10 mg/ml propidium iodide (PI; 30 min, 37uC) and analyzed by
flow cytometry. For annexin-V/PI double staining, cultured cells were stained using
an anti-annexin-V antibody kit (PharMingen; 15 min, 4uC). To distinguish live from
apoptotic and necrotic cells, 10 ml of 50 mg/ml PI stock solution was added before
flow cytometry analysis.
Western blot. Lysates (40 mg) of freshly isolated or cultured cells were analyzed with
anti-p21 (Santa Cruz) anti-phospho ERK antibodies (Cell Signaling); anti-ERK (Cell
Signaling), anti-CDK2 (Santa Cruz) and anti-b-actin (Sigma) served as loading
controls. Macrophage whole cell lysates (20 mg) were probed with anti-phospho-
STAT1 (Cell Signalling) and anti-iNOS (Abcam).
Immunoprecipitation and CDK2 kinase assay. For immunoprecipitation and
CDK2 kinase assay11, cells were lysed in buffer containing 50 mMTris-HCl (pH 7.5),
150 mM NaCl, 0.5% NP-40, protease inhibitor cocktail and phosphatase inhibitor
cocktail (Roche). Protein lysates (200 mg) were mixed with 2 mg anti-CDK2 (M2,
Santa Cruz; overnight, 4uC) and incubated with pre-blocked protein G-Sepharose
beads (25 ml, Invitrogen) for an additional 2 h. Anti-CDK2 immunoprecipitates were
then incubated with 20 ml kinase buffer (20 mM Tris-HCl (pH 8.0), 10 mMMgCl2,
1 mM EGTA, 1 mM dithiothreitol, 1 mM NaF, protease inhibitor cocktail and
phosphatase inhibitor cocktail), supplemented with 5 mg histone H1 (Roche),
0.5 mM ATP (Cell Signaling) and 10 mCi [c-32P]ATP (3000 Ci/mmol;
Perkin Elmer; 30 min, 30uC). Phosphorylated histone H1 was resolved by gel
electrophoresis.
Serological analysis. Relative levels of serum anti-DNA antibody were detected by
enzyme-linked immunosorbent assay (ELISA), as previously described42. The 96-well
plates were first coated with calf thymus DNA (2.5 mg/ml; Sigma Aldrich). IgG was
detected with peroxidase-conjugated anti-mouse antibody (Jackson
ImmunoResearch). Relative absorbance levels were measured at 492 nm in a
Labsystems Multiskan Plus Plate Reader. Proteinuria levels were determined at 4
months of age using Albustix strips andmeasurements were evaluated as 11, 21, 31,
41 (Bayer, Elkhart, IN). IFN-c levels in T cell-free supernatants were determined by
FlowMetrix system (Luminex, Austin, TX)11.
Kidney cryosections and immunofluorescence analysis. Kidneys were isolated,
embedded in inclusion solution (Jung Tissue Freezing medium, Leica Microsystems)
and frozen individually in liquid nitrogen. Cryosections (7 mm) were prepared in a
cryostat (Leica CM1900), placed on Fischer slides (Fisherbrand Superfrost/Plus) and
allowed to dry (2 h, RT). Sections were treated with 100% acetone (10 min, 4uC),
dried (30 min, RT) and blockedwith PBS1 2%BSA1 10%goat serum (45 min, RT).
After washing (3 times, PBS), sections were incubated (1 h, RT) with combinations of
anti-IgG-FITC, -CD4-PE (both from PharMingen), and -F4/80-FITC antibodies
(Serotec). After washing (3 times, PBS) and mounting (Vectashield, Vector
Laboratories), fluorescence was analyzed on a fluorescence microscope (Leica).
Glomerulonephritis evaluation. Kidney samples were fixed overnight in 10%
buffered formalin, embedded in paraffin, sectioned 4 mm thick and stained with
hematoxilin- eosin (H-E). Glomerulonephritis was graded on kidney sections
according to the Berden scale (62): (0) no glomerular lesions, (1) minimal thickening
of the mesangium, (2) lesions with noticeable increases in mesangial and
glomerular cellularity, (3) lesions characterized by the preceding conditions with
superimposed inflammatory exudates and capsular adhesions, and (4) glomerular
architecture was obliterated in .70% of glomeruli, and tubular cast formation was
extensive.
Survival analysis.The percentage of survivingmice over a 15-month time course was
calculated by the Kaplan-Meier method using GraphPad Prism V.5.
Statistical analysis. The Mann-Whitney U test was used for statistical analyses; p
values , 0.05 were considered significant.
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